Review Article


, Volume 74, Issue 8, pp 879-889

First online:

First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions

  • Antonio González-MartínAffiliated withMedical Oncology Department, MD Anderson Cancer Center Email author 
  • , Luisa Sánchez-LorenzoAffiliated withMedical Oncology Service, Hospital Central de Asturias
  • , Raquel BratosAffiliated withMedical Oncology Department, MD Anderson Cancer Center
  • , Raúl MárquezAffiliated withMedical Oncology Department, MD Anderson Cancer Center
  • , Luis ChivaAffiliated withGynecologic Oncology Department, MD Anderson Cancer Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in the frontline therapy of advanced epithelial ovarian carcinoma during the last decade. Maintenance chemotherapy or immunotherapy has not been proven to impact on overall survival and only one clinical trial that explored the administration of monthly paclitaxel for 1 year showed a benefit in terms of progression-free survival (PFS), but at the cost of maintained alopecia and increased peripheral neuropathy. This scenario may be changing with the incorporation of targeted therapy to the frontline therapy of ovarian cancer. In particular, anti-angiogenic therapy has been identified as the most promising targeted therapy, and the addition of bevacizumab to first-line chemotherapy followed by a maintenance period of bevacizumab in monotherapy has shown to prolong PFS. This was considered the proof of concept of the value of anti-angiogenic therapy in the frontline of ovarian cancer, and the results of two additional clinical trials with anti-angiogenic tyrosine-kinase inhibitors have shown results in the same direction.